Latest Pharma and Bio Collaborations

CarepathRx Health System Solutions and Evernorth Health Services Forge Strategic Partnership to Enhance Specialty Care for Patients

June 1
Last Trade: 257.03 3.64 1.44

BLOOMFIELD, Conn. and MERCER ISLAND, Wash., June 1, 2023 /PRNewswire/ -- CarepathRx Health System Solutions (CHSS), a CarepathRx company and portfolio company of Nautic Partners (Nautic), and Evernorth Health Services, a subsidiary of The Cigna Group (NYSE: CI), announced a new strategic partnership and investment by Evernorth in CHSS. The strategic partnership brings together Evernorth's diverse specialty and care expertise with CHSS'...Read more

NurExone Biologic and Particle Metrix Announce Collaboration in Extracellular Vesicles Analysis Using State-of-the-art Analytic Device

June 1
Last Trade: 0.25 0.00 0.00

MUNICH, Germany and TEL AVIV, Israel, June 01, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased to announce a pioneering collaboration with the German company, Particle Metrix, a leading provider of particle analysis devices. In...Read more

Charles River Laboratories and Wheeler Bio Announce Agreement to Build and Operate RightSourceSM Laboratory

May 31
Last Trade: 200.68 4.34 2.21

RightSource is Charles River’s insourced, purpose-built lab offering that provides industry-leading expertise conveniently placed within a client’s facility WILMINGTON, Mass. / May 31, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), today announced an agreement to implement RightSourceSM at Wheeler Bio’s current good...Read more

Cognetivity Neurosciences Announces Collaboration with Alzheimer's Society to Further Expand its AI Algorithms

May 31
Last Trade: 0.29 -0.01 -3.33

Agreement aims at further development of Cognetivity's AI (Artificial Intelligence) platform through investigating comorbidities in diabetes and dementia Vancouver, British Columbia--(Newsfile Corp. - May 31, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading provider of brain health solutions powered by AI, is excited to announce a collaboration with the...Read more

GeoVax Labs Partners With ABL to Advance cGMP Production of Vaccine Candidates

May 31
Last Trade: 0.62 -0.0057 -0.91

ATLANTA, GA, May 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced it has executed a Master Services Agreement (MSA) with Advanced Bioscience Laboratories, Inc. (ABL) to support current Good Manufacturing Practices (cGMP) production of the company’s vaccine candidates, including GEO-MVA...Read more

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

May 30
Last Trade: 3.39 0.03 0.89

C4 Therapeutics to Receive a $10 Million Upfront Payment, a $25 Million Equity Investment and is Eligible to Receive up to $357 Million for Development and Commercial Milestones Plus Royalties on Net Sales in Greater China Betta Pharmaceuticals to Develop and Commercialize CFT8919 in Greater China and Eligible to Receive Royalties on Net Sales Outside of Greater China The Exclusive Licensing Agreement with Betta Pharmaceuticals...Read more

BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases

May 30
Last Trade: 1.70 -13.59 -88.88

TEL AVIV, Israel, May 30, 2023 /PRNewswire/ -- BioLight (TASE: BOLT) is proud to report it has signed a research collaboration agreement with Alexion (AstraZeneca Rare Disease), focusing on exploring a groundbreaking technology that utilizes natural tears for the potential diagnosis of retinal diseases. The study, financed by Alexion and BioLight, will evaluate a screening technique (the "Technology") that analyzes...Read more

Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API Space

May 25
Last Trade: 1.62 -0.06 -3.57

RIJSWIJK, Netherlands and BOSTON, May 25, 2023 /PRNewswire/ -- Centrient Pharmaceuticals ("Centrient"), the global business-to-business leader in sustainable antibiotics, next-generation statins and anti-fungals, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced they are expanding their existing partnership aimed at broadening Centrient's portfolio of...Read more

Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute

May 24
Last Trade: 3.34 -0.04 -1.18

One of two newly announced clinical trials for its lead product candidate, PH-762 MARLBOROUGH, Mass., May 24, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced its clinical development partner, AgonOx, Inc, in collaboration with Providence...Read more

Azenta Announces Collaboration with the Lupus Research Alliance to Support the Advancement of Lupus Research and Drug Discovery

May 24
Last Trade: 44.21 0.68 1.56

Azenta has been Selected by the Lupus Research Alliance as its Sample Management Services Provider and Partner in Supporting the Development of the Patient Registry Component of the Lupus Nexus BURLINGTON, Mass., May 24, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics to support the development of the patient...Read more

Voyageur Pharmaceuticals Partners with Rain Cage Carbon to Revolutionize Medical Imaging with Nanocarbon-Based Contrast Drugs

May 24
Last Trade: 0.08 0.005 7.14

Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) ("Voyageur" or the "Corporation"), announces it has entered into a groundbreaking  development and license agreement with Rain Cage Carbon Inc. ("Rain Cage"). This strategic partnership aims to revolutionize the field by developing and manufacturing cutting-edge nanocarbon/fullerene-based contrast agents for medical imaging, utilizing Rain Cage’s innovative EDEN™ carbon capture...Read more

UCB and Veeva Systems Collaborate to Advance the Patient Experience in Clinical Trials

May 23
Last Trade: 195.00 -3.30 -1.66

Companies collaborate to set a new standard for patient-centric digital clinical trials BRUSSELS and PLEASANTON, Calif., May 23, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and UCB, a global biopharmaceutical company, today announced a collaboration that will focus on technology-driven solutions aimed at improving the patient experience and trial efficiency. The collaboration will see UCB adopt Veeva ePRO and Veeva...Read more

Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms

May 19
Last Trade: 2.22 -0.05 -2.20

ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems. The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the unprecedented precision and...Read more

Orgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors

May 18
Last Trade: 1.18 0.04 3.51

GERMANTOWN, Md. and PRAGUE, Czech Republic, May 18, 2023 (GLOBE NEWSWIRE) -- Orgenesis (NASDAQ: ORGS) (“Orgenesis”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) through its US-based point-of-care (POCare) services subsidiary, Morgenesis LLC (“Morgenesis”), has signed a collaboration agreement with SCTbio, a full-service contract development and manufacturing organization (CDMO)...Read more

Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission

May 17
Last Trade: 0.70 0.04 5.45

Pure-Vu Gastro achieves high usability scores in supporting upper endoscopy procedures with first time users - On track to submit a 510(k) to the U.S. FDA for the Pure-Vu Gen 4 Gastro device in Q4 2023 to support the 400,000 upper GI bleeds and other procedures with impaired visualization in the U.S.  Pure-Vu Gen 4 Gastro to be used during the 9th IECED Live Endoscopy Course 2023 through the Pentax Learning Center in June...Read more

Mednow Announces Partnership With Medcan Health Management to Deliver Collaborative, Interdisciplinary Healthcare

May 17
Last Trade: 0.28 0.005 1.82

Mednow, a leader in virtual pharmacy in Canada and Medcan, a leader in integrated, proactive healthcare and wellness services, announce partnership Mednow provides Medcan with concierge virtual pharmacy services, same-day medication home delivery and app-based consults with pharmacists. Mednow supports Medcan Year-Round Care and Dedicated Care clients with patient-first virtual pharmacy care and home delivery Mednow’s utilization of...Read more

Care PACE Signs with Tabula Rasa HealthCare for Expanded Services

May 17
Last Trade: 5.57 0.13 2.39

MOORESTOWN, N.J., May 17, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today announced that Mountain Empire PACE, a Program of All-Inclusive Care for the Elderly (PACE) in rural Virginia, has signed agreements with TRHC for personalized pharmacy services and pharmacy benefit management, expanding...Read more

IDEAYA Biosciences Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma

May 16
Last Trade: 24.87 0.95 3.97

Amended clinical trial collaboration and supply agreements with Pfizer to support evaluation of IDEAYA's planned Phase 2/3 registrational clinical trial to evaluate Daro + Crizo in 1L MUM Initiating Phase 2/3 registrational trial in Q2 2023 for darovasertib and crizotinib combination in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential AA SOUTH SAN FRANCISCO, Calif., May 16, 2023 /PRNewswire/ --...Read more

Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease

May 16
Last Trade: 25.21 0.47 1.90

SEATTLE, May 16, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe chronic kidney disease with significant unmet medical need. The companies will leverage Chinook’s precision medicine approach and deep expertise in...Read more

Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer

May 16
Last Trade: 2.06 0.14 7.29

Multicenter VOLTAGE-2 Phase II Trial Will Conduct Exploratory Biomarker Analysis Using Highly-Sensitive Genomic Platforms from Personalis FREMONT, Calif. & KASHIWA, Japan & OSAKA, Japan / May 16, 2023 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), National Cancer Center, and Ono Pharmaceutical Co., Ltd. today announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab, an...Read more

Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation

May 15
Last Trade: 77.89 1.68 2.20

Gilead to Have Early Option to Exclusively License Drug Candidates Against up to Four Targets for Inflammatory Diseases  Expanded Research Collaboration May Result in up to $1 Billion in Option Fees and Milestone Payments by Gilead to Arcus  FOSTER CITY, Calif., & HAYWARD, Calif. / May 15, 2023 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that the...Read more

Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases

May 12
Last Trade: 1.19 0.00 0.00

SOUTH SAN FRANCISCO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has entered into a research collaboration and development agreement with Xiamen Amoytop Biotech Co. Ltd. (“Amoytop”) for the use of Aligos’...Read more

Zhongchao Announces Strategic Cooperation with Ximalaya

May 12
Last Trade: 1.04 0.03 2.71

SHANGHAI, May 12, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Beijing Zhongchao Boya Medical Technology Co., Ltd. ("Boya Medical"), one of the Chinese operating entities of which the Company consolidates the financial results with through certain contractual...Read more

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

May 11
Last Trade: 104.20 1.38 1.34

New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation The new programs build on a successful first year of the...Read more

Gennev and LifeStance Health Partner to Provide Integrated Care for Women in Menopause

May 11
Last Trade: 8.46 0.14 1.68

National Partnership Unites Physical and Mental Healthcare to Improve Outcomes for Menopause Patients SEATTLE and SCOTTSDALE, Ariz., May 11, 2023 /PRNewswire/ -- Gennev, the nation's leading virtual menopause clinic provider, and LifeStance Health, one of the nation's largest providers of virtual and in-person outpatient mental healthcare, today announced a partnership to deliver integrated care that helps women address both the...Read more

Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology

May 10
Last Trade: 25.26 0.96 3.95

Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology Advancing the use of bicycle peptides as a novel targeting approach in radiopharmaceuticals Bicycle Therapeutics to receive upfront payment of USD 45 million, and potential future development and commercial-based milestones, up to a total of USD 1.7 billion, plus tiered...Read more

Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert

May 10
Last Trade: 5.79 0.14 2.48

Combination of DNA biomarkers with microbiome biomarkers has potential to enhance technical profile of novel pancreatic cancer screening test Joint research project to discover disease specific microbiome biomarkers BERKELEY, Calif. and MAINZ, Germany, May 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of...Read more

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next-Generation Sequencing-Based Testing for Cancer Patients in International Markets 

May 9
Last Trade: 520.14 0.76 0.15

Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access to localized advanced testing capabilities for breast and lung cancer in more than 30 countries where access to affordable advanced genomic testing is lacking or not available WALTHAM, Mass. / May 09, 2023 / Business Wire / Pfizer and Thermo Fisher Scientific Inc. (NYSE: TMO) today...Read more

Octarine Bio and Ginkgo Bioworks Announce Partnership to Produce Natural Colors

May 9
Last Trade: 1.62 -0.06 -3.57

COPENHAGEN, Denmark and BOSTON, May 9, 2023 /PRNewswire/ -- Octarine Bio, a synthetic biology company developing new sustainable bio-based ingredients, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a multi-stage partnership focused on compounds in the tryptophan pathway, with the objective of engineering a strain for producing violacein and its...Read more

Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing

May 9
Last Trade: 11.67 0.49 4.38


CytoMed Therapeutics Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology

May 9
Last Trade: 2.74 0.03 1.11

SINGAPORE, May 9, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, today announced it has entered into a research collaboration agreement with The University of Texas MD Anderson Cancer Center ("MD Anderson") in...Read more

Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease

May 9
Last Trade: 2.81 0.50 21.65

Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year...Read more

Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases

May 8
Last Trade: 1.62 -0.06 -3.57

BOSTON, May 8, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim. The two companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of...Read more

Galmed Pharmaceuticals Forms Strategic Partnership with OnKai

May 5
Last Trade: 4.74 0.11 2.38

TEL AVIV, Israel, May 4, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) reported today the execution of a definitive agreement for a $3M equity investment in OnKai Inc., leading an investment round of $6M. The agreement provides Galmed with a minority, but a strategic stake in Onkai. Concurrently, a strategic partnership agreement is being signed to advance both companies by leveraging their complementary knowledge and experience...Read more

Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets

May 4
Last Trade: 25.26 0.96 3.95

CAMBRIDGE, England, & BOSTON / May 04, 2023 / Business Wire / Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has entered into a collaboration with the German Cancer Research Center (DKFZ), to develop and discover Bicycle® radio conjugates (BRCs) for a range of oncology...Read more

TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases

May 4
Last Trade: 0.48 0.02 3.70

FORT WORTH, Texas, May 04, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has entered into a Collaborative Research and Development Agreement (CRADA) with the National Institute of Environmental Health...Read more

Labcorp And Jefferson Health Announce Strategic Laboratory Relationship

May 3
Last Trade: 216.98 4.54 2.14

Physicians and Patients Will Gain Access to Enhanced Laboratory Services and Advanced Diagnostic Testing Labcorp will acquire select assets of Jefferson's outreach laboratory services Jefferson will continue to own and operate their existing hospital labs for outpatient and inpatient services BURLINGTON, N.C., May 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement...Read more

Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications

May 3
Last Trade: 0.82 0.00 0.00

LONDON, Ontario, May 03, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel therapeutic cells. “Sernova has developed a novel cell therapy approach for...Read more

MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

May 3
Last Trade: 27.90 0.35 1.27

ZUG, Switzerland, May 3, 2023 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has signed a collaboration agreement with SHL Medical, a world-leading provider of advanced drug delivery solutions, to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake’s...Read more

Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials

May 2
Last Trade: 3.93 0.02 0.51

New supply agreement includes additional lots of intermediate drug product to support the manufacture of the rhenium (186Re) obisbemeda radiotherapeutic AUSTIN, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced an...Read more

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

May 1
Last Trade: 10.18 0.06 0.59

Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate from the companies’ ongoing collaboration to develop four TCR-based adoptive cell therapies targeting solid tumors Immatics to receive an option payment of $15 million and is eligible for additional up to $490 million in milestone payments in addition to tiered royalties on net sales of...Read more

2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program

May 1
Last Trade: 12.15 0.07 0.58

2seventy bio plans to present data at virtual Research and Development deep dive on May 19, 2023 CAMBRIDGE, Mass. / May 01, 2023 / Business Wire / 2seventy bio, Inc. (Nasdaq: TSVT) a leading immuno-oncology cell therapy company, today announced that it has achieved a preclinical $15 million milestone as part of the joint research and development collaboration focused on an in vivo gene editing treatment for hemophilia A. The milestone...Read more

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

May 1
Last Trade: 3.67 -0.04 -0.95

Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programs Development to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with...Read more

Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event

April 28
Last Trade: 22.73 1.68 7.98

Thirteen sunscreen dispensers, positioned at rest and lunch stops, will supply sunscreen to the more than 5,200 riders to protect their skin from sunburn during the two-day event FRIENDSWOOD, Texas / Apr 28, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has teamed up with IMPACT Melanoma, one of the nation's leading...Read more

Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology

April 27
Last Trade: 35.70 2.70 8.18

SHANGHAI, China and CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics (MediLink). MediLink is an innovative drug development company focusing on next generation anti-body-drug conjugates (ADCs) and related technologies. Through this collaboration, we have expanded our lung cancer...Read more

Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes

April 27
Last Trade: 3.55 0.17 5.03

NEW YORK, N.Y. and DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company pioneering the development and manufacturing of off-the-shelf, universally implantable bioengineered human tissues and organ systems, and JDRF International (JDRF), the leading global organization funding type 1 diabetes (T1D) research, today announced a new collaboration to advance the development of Humacyte’s...Read more

Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response

April 25
Last Trade: 32.39 1.00 3.19

Project will identify genomic and epigenomic biomarkers in patient blood samples from PICI’s RADIOHEAD study using GuardantINFINITY™ Goal of mission-focused collaboration is to help accelerate development and utilization of immune therapies for cancer PALO ALTO, Calif., & SAN FRANCISCO / Apr 25, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Parker Institute for Cancer...Read more

DocGo Announces Strategic Mobile Health Agreement with Fresenius Medical Care

April 25
Last Trade: 9.23 0.07 0.76

Collaboration Will Bolster Proactive Health Care Mission Via Remote Patient Monitoring, Chronic Care Management and More NEW YORK / Apr 25, 2023 / Business Wire / DocGo (Nasdaq:DCGO), a leading provider of last-mile mobile health services, today announced it has entered into a preferred provider agreement with Fresenius Medical Care (FMC) – the largest provider of kidney dialysis treatment in the United States. This preferred provider...Read more

ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

April 25
Last Trade: 8.32 0.94 12.74

SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a next generation CD47 blocker, and SARCLISA (isatuximab-irfc), Sanofi’s...Read more

Roche: Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting

April 24
Last Trade: 40.39 0.80 2.02

Roche, Genentech and partners embark on global prevalence research, trend-spotting with digital analysis, and telehealth initiatives to assess & address deterrents to brain health to better understand holistic health journeys of patients with neurologic diseases Long-term data to be presented demonstrate delayed MS disability with Ocrevus; reduced disease activity with Enspryng in NMOSD and with Evrysdi in SMA Data from late-stage...Read more

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

April 21
Last Trade: 0.62 -0.21 -24.95

The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™ TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with...Read more

Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies

April 20
Last Trade: 16.31 0.30 1.87

SOUTH SAN FRANCISCO, Calif. / Apr 20, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura., “Astellas”), by which Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for...Read more

Augmedix Announces Partnership with HCA Healthcare to Accelerate the Development of AI-enabled Ambient Documentation

April 20
Last Trade: 4.16 0.35 9.19

SAN FRANCISCO, April 20, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation, today announced a partnership with HCA Healthcare, Inc. (NYSE: HCA), one of the nation's leading healthcare providers, to accelerate development of technology that aims to transform the way patient care is documented in the acute care setting. Augmedix will collaborate...Read more

Cardinal Health launches Stray Away™ Hair Management Drape in collaboration with MedStar Health's Institute for Innovation

April 19
Last Trade: 84.59 1.17 1.40

DUBLIN, Ohio, April 19, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the launch of the first-of-its-kind Stray Away™ hair management drape for more efficient surgical procedure preparation. The Stray Away™ drape is specifically designed and manufactured by Cardinal Health to help minimize hair from obstructing the surgical area and to improve patient preparation time and experience. Pre-operative preparations for...Read more

Cambrium and Ginkgo Bioworks Complete Successful Collaboration on Data-Driven Cell Factory Engineering

April 18
Last Trade: 1.62 -0.06 -3.57

BERLIN and BOSTON, April 18, 2023 /PRNewswire/ -- Cambrium, a leading German start-up focused on the application of generative AI to protein design and synthesis, and Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of their collaboration. Through the partnership, Cambrium and Ginkgo combined their capabilities to enable the rapid...Read more

Monaghan Medical and Premier Sign AscenDrive Contract

April 18
Last Trade: 25.82 0.76 3.03

PLATTSBURGH, N.Y., April 18, 2023 (GLOBE NEWSWIRE) -- Monaghan Medical Corporation (Monaghan) and Premier, Inc., today announced their agreement to a three-year contract, effective May 1, 2023, creating a partnership between two healthcare industry leaders. Through this partnership, Monaghan will provide Premier AscenDrive Program members with respiratory devices in two categories: Respiratory Therapy Medication Delivery devices and...Read more

Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement

April 18
Last Trade: 0.30 0.01 4.03

SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has entered into a clinical trial agreement with Brigham and Women’s Hospital for the evaluation of CP101, a Complete Consortia microbiome therapeutic, in ulcerative...Read more

Awakn Life Sciences Signs Collaboration Agreement with University of Exeter for Upcoming Phase III Trial

April 18
Last Trade: 0.28 0.00 0.00

Phase III Trial Will Assess Ketamine-Assisted Therapy for the Treatment of Severe Alcohol Use Disorder Toronto, Ontario--(Newsfile Corp. - April 18, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that it has signed a collaboration agreement with the University of Exeter...Read more

Ginkgo Bioworks and Syngenta Seeds Announce Collaboration to Develop New Traits for the Next Generation of Seed Technology

April 17
Last Trade: 1.62 -0.06 -3.57

Partnership will leverage Ginkgo's cell programming capabilities to support Syngenta's ongoing seeds R&D pipeline efforts BOSTON, April 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and Syngenta Seeds ("Syngenta"), one of the world's leading agricultural technology companies, today announced a research partnership focused on screening a targeted...Read more

argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

April 17
Last Trade: 395.80 1.14 0.29

Genmab and argenx have entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway Amsterdam, the Netherlands – 04/17/2023 argenx SE (Euronext & Nasdaq: ARGX) and Genmab A/S (Nasdaq: GMAB) announced today that argenx and Genmab have entered into a collaboration agreement...Read more

Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

April 17
Last Trade: 1.94 0.03 1.57

Lipella to collaborate in anticipation of forthcoming Investigational New Drug (IND) application LP-10 is a promising potential treatment for hemorrhagic cystitis that has received Orphan Drug Designation from the FDA Lipella has successfully completed a Phase 2a clinical trial evaluating LP-10 PITTSBURGH, April 17, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage...Read more

Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies

April 13
Last Trade: 1.62 -0.06 -3.57

Collaboration with University of Wisconsin Professors Krishanu Saha (PI) and Christian Captini (co-PI) to discover novel and improved GD2 CAR designs to treat solid tumors and validate them in vivo MADISON, Wis. and BOSTON, April 13, 2023 /PRNewswire/ -- The Wisconsin Alumni Research Foundation (WARF), which has a mission of supporting research at the University of Wisconsin-Madison, and Ginkgo Bioworks (NYSE: DNA), which is...Read more

Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline

April 12
Last Trade: 7.46 0.41 5.82

SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a translational collaboration with Takeda to use its clonoSEQ® Assay to assess minimal residual disease (MRD) to facilitate the development and...Read more

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

April 12
Last Trade: 31.52 0.60 1.94

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV):Amyloid beta program (ATV:Aβ). Accumulation of Aβ plaque in the brain is a defining feature of Alzheimer’s disease (AD). Using Denali’s ATV platform to cross the blood-brain...Read more

Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program

April 12
Last Trade: 23.43 0.33 1.43

SALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed® Imaging, one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, today announced the planned launch of a new hereditary cancer assessment program that combines diagnostic imaging, genetic risk assessment utilizing...Read more

ClearPoint Neuro Extends Software License and Research Agreement with Philips to Include Fully Automatic Subnuclei Segmentation for DBS

April 11
Last Trade: 7.77 0.07 0.91

SOLANA BEACH, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced further expansion of its worldwide license and research agreement with Philips, a global leader in health technology, to add subnuclei segmentation applied to MRI, and potentially CT scans, for use in the operating room....Read more

Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research

April 11
Last Trade: 40.33 -0.37 -0.91

Strategic partnership between Mission Bio and Fulgent Genetics will enable drug developers to leverage single-cell multi-omics for biomarker discovery, clinical research, and single-cell MRD development at scale SOUTH SAN FRANCISCO, Calif., April 11, 2023 /PRNewswire/ -- Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced that it has entered into an agreement with Fulgent...Read more

Xenetic Biosciences Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

April 11
Last Trade: 3.19 0.28 9.62

Collaboration provides a significant step forward in the advancement of Xenetic's DNase-based oncology program towards Phase 1 clinical development Systemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinoma FRAMINGHAM, MA / ACCESSWIRE / April 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative...Read more

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

April 11
Last Trade: 0.90 0.01 1.12

The global market access and expansion partnership, initially established in 2015, aims to provide an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) Diagnosis plays a critical role in guiding patients towards appropriate and readily available therapies that can enhance their quality of life CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V....Read more

Cardio Diagnostics Announces Strategic Engagement with to Drive Longevity & Heart Disease Research and Education

April 5
Last Trade: 1.43 0.01 0.70

CHICAGO / Apr 05, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced a strategic engagement with, a leading nonprofit advocacy foundation and online platform focusing on the extension of healthy human lifespan through research and education. This engagement seeks to enhance public awareness and create comprehensive...Read more

CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation

April 5
Last Trade: 1.00 0.08 8.40

CareDx Exclusive Provider of dd-cfDNA Testing Services for Use in Miromatrix Clinical Trials Companies at Forefront of Alternative Organ Supply Research to Address Organ Shortage BRISBANE, Calif. and EDEN PRAIRIE, Minn., April 05, 2023 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) and Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO) -- today announced an exclusive partnership aimed at advancing the next wave of innovation...Read more

OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND

April 5
Last Trade: 0.70 -0.0012 -0.17

Parties add several deliverables to initial R&D collaboration contract Overall potential revenue increased to up to euro 830 thousand ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that it signed an amendment to its research...Read more

Solvay Announces Strategic Collaboration With Ginkgo Bioworks And Expands Its R&I Footprint In The United States

April 4
Last Trade: 1.62 -0.06 -3.57

The investment will accelerate the development of new sustainable biopolymers, strengthening Solvay's position in biotechnology in this important growth platform. BRUSSELS and BOSTON, April 4, 2023 /PRNewswire/ -- Solvay, a leading science and materials company whose technologies bring benefits to many aspects of daily life, today announced a strategic collaboration with Ginkgo Bioworks (NYSE: DNA), which is building the leading...Read more

Absci Partners with Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology

April 4
Last Trade: 1.88 0.04 2.17

VANCOUVER, Wash. and TAMPA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and M2GEN, an oncology bioinformatics company with the most advanced lifetime-consented clinicogenomics data to accelerate discovery research, today announced a partnership to create new cancer medicines and bring them to market at unprecedented speed. Absci’s generative AI drug creation platform...Read more

Enlivex Therapeutics Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates

April 4
Last Trade: 2.65 0.11 4.13

Clinical collaboration with BeiGene announced on April 3, 2023 to evaluate the safety and efficacy of Allocetra™, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors, a part of the Company’s ongoing Phase I/II clinical trial. Planned amendment to be filed with regulators in early Q2 2023 for...Read more

BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

April 3
Last Trade: 108.13 4.01 3.85

BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human cancers Collaboration will add a new class of precision medicine therapeutics to BioNTech’s clinical-stage oncology portfolio, expanding the breadth of its immunotherapy toolkit with synergistic potential DualityBio receives upfront payments...Read more

Sensible Biotechnologies Announces Partnership with Ginkgo Bioworks to Develop Novel mRNA Manufacturing Platform

April 3
Last Trade: 1.62 -0.06 -3.57

Through this partnership, Sensible and Ginkgo aim to develop an in vivo alternative to conventional in vitro mRNA production technology OXFORD, United Kingdom, April 3, 2023 /PRNewswire/ -- Sensible Biotechnologies, an early stage biotechnology company, today announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming...Read more

Enlivex Therapeutics Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

April 3
Last Trade: 2.65 0.11 4.13

Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today announced a clinical collaboration with BeiGene. to evaluate the safety and efficacy of Allocetra™, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients...Read more

OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics

April 3
Last Trade: 0.70 -0.0012 -0.17

PREPLEX project is part of broader InfectoGnostics Research Campus in Jena, Germany Total project volume of PREPLEX collaborative research is approximately $ 0.9 Mio ROCKVILLE, Md., April 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that it has...Read more

Panbela Therapeutics Announces New Research Agreement with Johns Hopkins University School of Medicine

April 3
Last Trade: 6.58 0.22 3.46

MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a new research agreement with the Johns Hopkins University School of Medicine. The collaboration is intended to expand the development of Panbela’s investigative agent ivospemin (SBP-101), including activity in...Read more

Holland PHO and agilon health Form Partnership to Expand the Delivery of Value-based Primary Care in West Michigan

March 30
Last Trade: 20.22 0.95 4.93

The partnership supports Holland PHO and agilon’s efforts to transform health care for seniors agilon’s Total Care Model expands to more Michigan communities through new partnership HOLLAND, Mich & AUSTIN, Texas / Mar 30, 2023 / Business Wire / Holland PHO, a Physician-Hospital Organization, with a mission to deliver quality and efficient health care to communities it serves, today announced it will enter a long-term partnership...Read more

Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™

March 30
Last Trade: 2.82 0.20 7.63

CHICAGO / Mar 30, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, today announced that it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals, Inc. Under the terms of the agreement, Xeris...Read more

Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy

March 30
Last Trade: 3.53 0.20 6.01

EAGAN, Minn., March 30, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announces it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases. The collaboration was created to pursue a novel method to enhance Integra Therapeutics’ ability to use...Read more

ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas

March 30
Last Trade: 3.13 -0.08 -2.63

Agreement Focuses on in silico and de novo Discovery and Development of Antibodies Against Tumor Microenvironment Targets. Program will Leverage BioStrand’s (a Talem Affiliate) LENSai® Integrated Intelligence Technology®, Built Upon the Proprietary HYFT Index®. VICTORIA, British Columbia / Mar 30, 2023 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic...Read more

G Medical Innovations And Adventhealth In Joint Collaboration To Provide Innovative Remote Patient Monitoring Solutions For Adventhealth Patients In Central Florida

March 29
Last Trade: 0.38 -0.0036 -0.95

Rehovot, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical Innovations”), a global leader in next-generation mobile health (mHealth) and digital health, today announced that its wholly-owned subsidiary, G Medical Innovations USA, Inc., has entered into an agreement with AdventHealth Central Florida (“AdventHealth”) to expand the health care system’s remote patient...Read more

Regeneron Pharmaceuticals and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases

March 28
Last Trade: 739.95 8.78 1.20

TARRYTOWN, N.Y., and SOUTH SAN FRANCISCO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma Biotherapeutics, Inc. today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will...Read more

Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology

March 28
Last Trade: 47.47 1.52 3.31

Drug discovery services partnership with Sino-American Cancer Foundation focuses on the development of actionable hits against the MTHFD2 target LANCASTER, Calif. / Mar 28, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it established a strategic research collaboration with the Sino-American...Read more

Covant Therapeutics and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients

March 28
Last Trade: 9.44 0.09 0.96

BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim covering Covant’s ADAR1 program. The companies jointly aim to develop a novel small molecule immunotherapy targeting ADAR1 to transform the lives of cancer patients. Covant significantly accelerates drug discovery for...Read more

Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates

March 28
Last Trade: 25.26 0.96 3.95

Bicycle and Novartis will collaborate on the discovery and development of multiple targeted radioligand therapies in oncology Bicycle will receive a $50 million upfront payment as well as potential milestones and tiered commercial royalties CAMBRIDGE, England & BOSTON / Mar 28, 2023 / Business Wire / Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on...Read more

Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt

March 28
Last Trade: 0.71 0.01 1.79

AD Ports Logistics, subsidiary of AD Ports Group's Logistics Cluster, chosen as the Exclusive Distributor for UAE, Qatar, Bahrain, Oman, Kuwait and Egypt Product distribution agreement opens access to Celularity's Halal-Certified regenerative medicines, health and wellness products across the Middle East News follows the previously-announced Product Distribution Agreement for the Kingdom of Saudi Arabia  FLORHAM PARK,...Read more

Sign Up To Get Daily Health Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...